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Abstract
Background: In patients with advanced hepatocellular carcinoma (HCC), combination chemotherapy using 5-
fluorouracil, cisplatin, and mitoxantrone (FMP) could achieve a response rate > 20%, but the beneficial effect was
compromised by formidable adverse events. Chemotherapy given in a split-dose manner was associated with
reduced toxicities. In this retrospective study, we compared the efficacies and side effects between a regular and a
split-dose FMP protocol approved in our medical center.
Methods: From 2005 to 2008, the clinical data of 84 patients with far advanced HCC, who had either main portal
vein thrombosis and/or extrahepatic metastasis, were reviewed. Of them, 65 were treated by either regular (n = 27)
or split-dose (n = 38) FMP and had completed at least one therapeutic course. The remaining 19 patients were
untreated. Clinical parameters, therapeutic responses, survivals and adverse events were compared.
Results: The median overall survival was 6.0, 5.2, and 1.5 months, respectively, in patients receiving regular FMP,
split-dose FMP, and no treatment (regular versus split-dose group, P = 0.447; regular or split-dose versus
untreated group; P < 0.0001). Patients receiving split-dose treatment had a significantly lower risk of grade 3/4
neutropenia (51.9 versus 10.5%, P = 0.0005). When the two treated groups were combined, the median overall
survival was 10.6 and 3.8 months respectively for patients achieving disease control and progressive disease (P <
0.001). Cox proportion hazard model identified Child-Pugh stage B (hazard ratio [HR], 2.216; P = 0.006), presence
of extrahepatic metastasis (HR, 0.574; P = 0.048), and achievement of disease control (HR, 0.228; P < 0.001) as
independent factors associated with overall survival. Logistic regression analysis revealed that anti-hepatitis C
virus antibody (odds ratio [OR], 9.219; P = 0.002) tumor size (OR, 0.816; P = 0.036), and previous anti-cancer
therapy (OR, 0.195; P = 0.017) were significantly associated with successful disease control.
Conclusions: Comparable overall survival was observed between patients receiving regular and split-dose FMP
therapies. Patients receiving split-dose therapy had a significantly lower risk of grade 3/4 neutropenia. Positive anti-
hepatitis C virus antibody, smaller tumor size, and absence of previous anti-cancer therapy were independent
predictors for successful disease control.
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Hepatocellular carcinoma (HCC) is the fifth most com-
mon solid malignancy and the third leading cause of
cancer death in the world [1]. The major attributive fac-
tors include chronic hepatit i sBv i r u s( H B V )i n f e c t i o n ,
chronic hepatitis C virus (HC V )i n f e c t i o na n da l c o h o l i c
liver diseases [2-4]. Early stage HCC can be cured by
surgical resection, non-surgical ablation procedures or
liver transplantation [5]. Although the 5-year survival
rate reached over 50%, the recurrence rate remained
high, reaching over 80% at the fifth year after surgical
resection [5,6]. On the other hand, for patients with
unresectable HCC, a standard therapy has yet to be
established.
Transcatheter arterial chemoembolization (TACE) is
believed to be beneficial in patients without main portal
vein occlusion or extrahepatic metastasis. To date, no
large-scale randomized study has been conducted to illus-
trate its beneficial effect. However, a profound difference
in survival has been observed in small-scale case control
studies as well as intent-to-treat studies [7-15]. Sorafenib
has been shown to improve survival in unresectable HCC
patients in two large-scale phase-III randomized con-
trolled studies [16,17]. In the SHARP study, the median
survival improved from 7.9 to 10.7 months and in Asia-
Pacific study, the median survival improved from 4.2 to
6.5 months. Despite encouraging data, in both studies, it
was shown that patients with extrahepatic metastasis
could not significantly benefit from sorafenib therapy. In
this subgroup of patients, systemic chemotherapy
remained an option. Several phase-II trials using various
chemotherapy regimens have been conducted for treat-
ment of advanced HCC [18]. Among these regimens, only
a few achieved response rates higher than 20%. When a
single agent was used, doxorubicin could achieve a
response rate of 32% in one study. When combination
chemotherapy regimens were used, only three com-
binations have been shown to achieve a response rate
greater than 20%. They are epirubicin + etoposide (39%),
cisplatin + doxorubicin + 5-fluorouracil + alpha-interferon
(PIAF, 26%), and mitoxantrone +5-fluorouracil + cisplatin
( F M P ,2 7 % )[ 1 9 ] .T h er e s p o n s er a t eo fF M Pi nt h el a t t e r
trial is consistent with that of another independent trial
(23.8%) [20]. Despite substantial response rates, formidable
side effect usually developed in a great proportion of
patients, deterring the clinical application of these regi-
mens in far advanced HCC. To date, no randomized con-
trolled study ever conducted to clarify whether overall
survivals can be prolonged with these agents. According to
a large-scale study conducted in Taiwan, the overall survi-
val for patients with far advanced HCC was 1.6 month
[21], demonstrating the urgent for an effective therapeutic
modality.
A recent advance in the strategy of chemotherapy is
that chemotherapy can be performed in a split-dose
manner with lower side effects [22]. This method, called
metronomic chemotherapy, has now been widely
adapted to various chemotherapy protocols. In our med-
ical center, a regular and a split-dose protocol of FMP
have been approved for the treatment of patients with
advanced HCC. In this retrospective study, we compared
the performance of these two protocols. The exploratory
purpose of the present study was to investigate whether
a split-dose FMP protocol was clinically acceptable for
treatment of far advanced HCC and to justify the use of
split-dose protocol in future clinical trials.
Methods
Patients
This was a retrospective study approved by the institu-
tional review board of Chang Gung Memorial Hospital
(IRB98-2109B). From June, 2005 to August, 2008, 4059
patients were diagnosed to have HCC in Chang Gung
Medical Center. Of them, 894 (22%), 648 (16%), 1233
(30%), 462 (11%), and 822 (20%) patients received
operation, radio-frequency ablation, TACE, chemother-
apy, and no treatment, respectively. Of the 462 patients
receiving chemotherapy, 286 patients were eligible and
enrolled in various clinical trials, whereas in the remain-
ing 176 patients, different approved single or combina-
tion anti-cancer agents were used. Of the 176 patients,
71 were diagnosed as far advanced HCC in the Depart-
ment of Hepato-gastroenterology and had received FMP
combination chemotherapy. Of these 71 patients, 65 had
completed at least one course of FMP therapy and were
included in this study. The remaining 6 patients were
excluded due to failure to complete the first therapeutic
course. Clinical parameters were recorded, including
sex, age, HBV or HCV markers, alcoholism, ECOG per-
formance status, clinical cirrhosis, portal vein thrombo-
sis, tumor size, ascites, alpha-fetoprotein, previous
treatment, distal metastasis, Child-Pugh classification,
Okuda staging, Cancer of the Liver Italian Program
(CLIP) score, treatment protocol used, and number of
treatment courses. All patients included belonged to the
advanced Barcelona Clinic Liver Cancer (BCLC) stage
(stage C). Two different treatment protocols were avail-
able in our hospital, the regular and the split-dose pro-
tocols. The decision with regards to therapeutic
methods was made after discussion between the attend-
ing hepatologists and the patients. HCC was diagnosed
by biopsy or aspiration cytology. Alternatively, if tissue
or cytology proof could not be obtained, HCC was diag-
nosed by high AFP levels (> 400 ng/mL) plus two
dynamic image studies (dynamic computer tomography
and angiography).
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had main portal vein thrombosis and/or extrahepatic
metastasis (not suitable for TACE); ECOG performance
status 0-2; never received systemic chemotherapy except
chemoembolization; adequate hematological data
(hemoglobin > 9 g/dL; white blood cells > 2000 cells/
mm
3; neutrophils > 1000 cells/mm
3;p l a t e l e tc o u n t>
60,000 cells/mm
3); adequate liver function (Child-Pugh
classification A or B); and adequate renal function
(serum creatinine within normal limits). The bilirubin
levels were all ≦ 6.5 mg/dL except for two patients, who
had bilirubin levels 23.4 and 24.5 mg/dL respectively
because of tumor invasion to main biliary tree (Table 1).
Another group of 19 patients with far advanced HCC,
who had documented survival time, were also included.
They all had main portal vein thrombosis and/or extra-
hepatic metastasis, ECOG performance status 0-2, and
Child-Pugh functional class A or B. These patients did
not receive any treatment following the diagnosis of
HCC and were included as untreated controls. One of
these patients had a bilirubin level of 8.7 mg/dL due to
tumor invasion to biliary tree; otherwise all bilirubin
levels were ≦ 6.5 mg/dL (Table 1).
Treatment protocols
Regular protocol
5-FU was administered continuously via intravenous
route at a dose of 450 mg/m2 on Days 1-5. Mitoxan-
trone was administered as an intravenous infusion at a
dose of 6 mg/m2 on Day 1. Cisplatin was administered
as an intravenous infusion at a does of 80 mg/m2 over
2 hours on Day 1 with standard hydration. The does
used in the subsequent course was adjusted to the toxi-
cities observed. Granulocyte colony-stimulating factor
was given when neutropenia and/or leukocytopenia of
Grade 3/4 were observed. The treatment was repeated
every 4-6 weeks until reaching a maximum of 6 courses.
Split-dose protocol
T h es c h e d u l ew a st h es a m ea st h er e g u l a rp r o t o c o lo n e
except that only a 1/2 dose of mitoxantrone and cispla-
tin were given on Day 1. On the ninth day, the bio-
chemical and hematological data were checked. If the
hematological, liver function, and renal function data
were adequate, 1/4 dose of mitoxantrone and cisplatin
were given on Day 9 and Day 10, respectively. The
treatment was repeated every 4-6 weeks until reaching a
maximum of 6 courses.
Response and toxicity evaluation
The objective tumor response was assessed by computer
tomography every 4-8 weeks after the beginning of FMP
therapy and was evaluated according to the following
criteria. Complete response (CR) was defined as the
complete disappearance of all target lesions without any
residual lesion. Partial response (PR) was defined as a >
50% decrease in tumor mass, without progression in any
target lesion or appearance of a new lesion. Minor
response (MR) was defined as a > 25% decrease in total
tumor masses. Stable disease (SD) was defined as either
a < 25% decrease or a < 25% increase of total tumor
masses. Progressive disease (PD) was defined as a > 25%
increase in total tumor masses. Clinical responders were
patients achieving CR, PR or MR. Disease control was
achieved in patients with CR, PR, MR or SD.
Adverse effects were evaluated according to the NCI
Common Terminology Criteria for Adverse Events
(CTCAE) version 3.0.
Statistical analysis
Dichotomized data was expressed as ratios (%) and com-
pared by use of Fisher’s exact test; parametric data was
expressed as mean ± standard deviation and compared
b yu s eo f2 - s a m p l ett e s t ;n o n - p a r a m e t r i cd a t ao rd a t a
not in normal distribution was expressed as median
(range) and compared by Mann-Whitney test. Overall
survival was calculated from the date of treatment to
the date of death or last follow-up. Time to disease pro-
gression was calculated from the date of treatment to
the date of PD. In univariate analysis, the Kaplan-Meier
method was used to estimate the survival probability
and the log-rank test was used to compare the survivals
between groups. Independent predictive factors affecting
survival were analyzed by the Cox multivariate propor-
tional hazards regression model. In this study, significant
factors identified from univariate analysis were included
for Cox proportional hazards analysis. Additionally, to
follow the rule of 1 variable for 10 deaths, 6 most signif-
icant factors obtained from univariate analysis were
selected for additional Cox model analysis. Independent
predictors affecting disease control rate were analyzed
by Logistic regression analysis. Only significant factors
identified from univariate analysis were included. P <
0.05 was considered statistically significant. Statistical
analysis was conducted by using SPSS (version 13.0).
Results
Basic clinical data in far advanced HCC patients included
in this study
Of 84 patients included, 27 and 38 patients received reg-
ular and split-dose FMP therapy, respective, whereas 19
patients received no therapy. The basic clinical data are
listed in Table 1. No statistical difference was found
between the two treated groups in any of the pre-thera-
peutic clinical parameters. However, more patients in
the split-dose group received only one course of FMP
combination chemotherapy (regular versus split-dose
groups, 9/27 (33.3%) versus 25/38 (65.8%); P = 0.018).
When compared either of the two treated groups and
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Regular
Group
Split-dose
Group
Untreated
Group
P (Regular vs.
Untreated)
P (Split-dose vs.
Untreated)
P (Regular vs.
Split-dose)
Number of patients 27 38 19
Age in years, average ± SD 61.0 ± 10.1 54.8 ± 14.9 62.8 ± 12.5 NS 0.049 NS
Gender (Male/Female) 21/6 31/7 16/3 NS NS NS
Etiology
HBsAg (+) 19 (70.4%) 27 (71.1%) 10 (52.6%) NS NS NS
Anti-HCV (+) 9 (33.3%) 11 (28.9%) 5 (26.3%) NS NS NS
HBsAg (+)/anti-HCV (+) 1 1 0 - -
HBsAg (-)/anti-HCV (-) 0 1 4 - -
Alcoholism 11 (40.7%) 21 (55.3%) 7 (36.8%) NS NS NS
ECOG performance status NS
a NS
a NS
a
0 9 19 7
11 2 1 0 6
26 9 6
Diagnosis - - -
Biopsy 5 10 4
Cytology 9 9 0
Imaging + alpha-fetoprotein 13 19 15
Liver cirrhosis 27 (100%) 36 (94.7%) 17 (89.5%) NS NS NS
Tumor size in cm, average ± SD 6.62 ± 3.81 7.99 ± 4.55 8.71 ± 3.42 NS NS NS
Alpha-fetoprotein in ng/mL,
median (range)
448
(3-62208)
2338
(3-248421)
1491
(3 - 377218)
NS NS NS
Portal vein thrombosis 15 (55.6%) 22 (59.5%) 13 (68.4%) NS NS NS
Metastasis 19 (70.4%) 19 (50%) 10 (52.6%) NS NS NS
Lymph node 10 10 4
Lung 8 10 7
Bone 1 2 1
Duodenum 1 0 0
Adrenal gland 1 0 0
Kidney 0 1 0
Heart 0 1 0
Inferior vena cava 0 1 0
Child-Pugh stage
A 16 (59.3%) 22 (57.9%) 10 (52.6%) NS NS NS
B1 1 1 6 9
Bilirubin in mg/dL, average ± SD 1.44 ± 0.88 2.66 ± 5.20
b 2.86 ± 2.36
c 0.006 NS NS
Previous therapy 18 (66.7%) 18 (47.4%) No - - NS
Percutaneous local ablation 3 2
TACE 15 13
Partial hepatectomy 3 3
Radiotherapy 1 3
Course of FMP chemotherapy
received
1 9 (33.3%) 25 (65.8%) 0 - - 0.018
21 1 9 0
32 2 0
>3 3 1 0
aPerformance status was compared between ECOG 0 and ECOG 1+2 groups.
bTwo patients had obstructive jaundice with bilirubin 23.4 and 24.5 mg/dL, respectively.
cOne patient had obstructive jaundice with bilirubin 8.7 mg/dL.
NS, not significant (P > 0.05).
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untreated group were borderline older than those in
split-dose group (62.8 ± 12.5 versus 54.8 ± 14.9 years;
P = 0.049). Additionally, patients in untreated group had
higher bilirubin level than those in regular group (2.86 ±
2.36 versus 1.44 ± 0.88 mg/dL; P = 0.006). Such differ-
ence, however, was not observed between patients in the
untreated and split-dose group (Table 1). Logistic regres-
sion analysis also failed to identify any clinicopathological
factor significantly associated with the choice of either
protocol. All except 3 responders and 2 patients with
progressive diseases were followed till death.
Clinical responses and associated factors
In patients on regular and split-dose protocols, 14/27
(51.9%) and 12/38 (31.6%) patients respectively
achieved disease control (P = 0.127). The numbers of
patients achieving CR, PR, MR, and SD were listed in
Table 2. In the two groups of patients, the median
o v e r a l ls u r v i v a lw a s6 . 0a n d5 . 2m o n t h s ,r e s p e c t i v e l y
(P = 0.447) and the median time to disease progression
was 3.1 and 2.2 months, respectively (P = 0.199). In
contrast, the median overall survival was only 1.5
months in untreated patients (regular or split-dose
versus untreated group; P < 0.0001; power = 99.6%
[regular] and 99.3% [split-dose], respectively) (Figure 1A).
In patients on regular protocol, the median overall survival
was 7.5 and 4.5 months for patients achieving disease
control and progressive disease, respectively (P = 0.002).
In patients on split-dose protocol, the median overall
survival was 14.0 and 3.6 months for patients achieving
disease control and progressive disease, respectively (P <
0.001) (Figure 1B).
Univariate analysis was conducted to identify factors
associated with clinical responses, disease control, and
overall survival (Table 3). Two factors were associated
with higher clinical response rates: absence of previously
anti-cancer therapy (44.8 versus 13.9%, P = 0.011) and
completion of more than one course of FMP che-
motherapy (45.2 versus 11.8%, P = 0.005). Seven factors
were associated with higher disease control rates: age
older than 60 years (57.1 versus 27.0%, P = 0.021), posi-
tive anti-HCV antibody (70.0 versus 26.7%, P = 0.002),
negative serum HBV surface antigen (HBsAg) (63.2 ver-
sus 30.4%, P = 0.025), total tumor diameters less than or
equal to 8 cm (54.8 versus 13.0%, P = 0.001), absence of
previously anti-cancer therapy (55.2 versus 27.8%, P =
0.041), CLIP score 1 or 2 (55.6 versus 28.9%, P = 0.041)
and completion of more than one course of FMP che-
motherapy (64.5 versus 17.6%, P < 0.001).
Table 2 Treatment outcome in patients receiving regular or split-dose FMP therapy
Patients achieving disease control
Responders Patients with progressive disease
Group Total CR PR MR SD
Regular 27 2 4 3 5 13 (48.1%)
Split-dose 38 0 4 5 3 26 (68.4%)
Regular vs. split-dose protocol: disease control rate, P = 0.127; response rate, P = 0.414.
Figure 1 Survival analysis of patients with advanced HCC treated by FMP. (A) Overall survival in the two treated groups and the untreated
group of patients. (B) Overall survival in the two groups of patients (regular and split-dose) achieving disease control and progressive diseases.
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Page 5 of 10Table 3 Univariate analysis for prognosis factors
Factors No. of patients Responder P Disease control P Median survival (months) P
Sex Male 52 13 (25.0%) 0.489 18 (34.6%) 0.114 5.6 0.374
Female 13 5 (38.5%) 8 (61.5%) 7.4
Age ≦ 60 years 37 9 (24.3%) 0.580 10 (27.0%) 0.021 5.1 0.050
> 60 years 28 9 (32.1%) 16 (57.1%) 7.0
anti-HCV (-) 45 10 (22.2%) 0.229 12 (26.7%) 0.002 5.4 0.033
(+) 20 8 (40.0%) 14 (70.0%) 7.6
HBsAg (-) 19 7 (36.8%) 0.364 12 (63.2%) 0.025 7.4 0.115
(+) 46 11 (23.9%) 14 (30.4%) 5.6
Alcoholism (-) 33 11 (33.3%) 0.407 15 (45.5%) 0.450 6.0 0.611
(+) 32 7 (21.9%) 11 (34.4%) 5.8
ECOG 0 28 10 (35.7%) 0.267
a 13 (46.4%) 0.446
a 7.0 0.011
a
1 22 6 (27.3%) 11 (50.0%) 6.1
2 15 2 (13.3%) 2 (13.3%) 3.6
Cirrhosis (-) 2 0 (0%) 0.999 0 (0%) 0.513 11.5 0.830
(+) 63 18 (27.7%) 26 (40%) 6.0
Portal vein thrombosis (-) 28 8 (28.6%) 0.999 12 (42.9%) 0.799 6.0 0.319
(+) 37 10 (27.0%) 14 (37.8%) 5.5
Tumor size ≦ 8 cm 42 15 (35.7%) 0.081 23 (54.8%) 0.001 7.1 0.001
> 8 cm 23 3 (13.0%) 3 (13.0%) 4.2
Ascites (-) 41 10 (24.4%) 0.567 16 (39.0%) 0.999 6.0 0.014
(+) 24 8 (33.3%) 10 (41.7%) 3.6
Alpha-fetoprotein ≦ 10000 ng/mL 50 13 (26.0%) 0.743 21 (42.0%) 0.764 7.5 0.098
> 10000 ng/mL 15 5 (33.3%) 5 (33.3%) 4.3
Previous treatment (-) 29 13 (44.8%) 0.011 16 (55.2%) 0.041 6.1 0.750
(+) 36 5 (13.9%) 10 (27.8%) 5.2
Extrahepatic metastasis (-) 27 7 (25.9%) 0.999 8 (29.6%) 0.201 3.7 0.014
(+) 38 11 (28.9%) 18 (47.4%) 7.1
Child-Pugh A 38 9 (23.7%) 0.414 13 (34.2%) 0.309 7.0 0.012
B 27 9 (33.3%) 13 (48.1%) 3.8
Okuda stage I 27 10 (37.0%) 0.173
b 14 (51.9%) 0.127
b 7.0 0.004
c
II 28 5 (17.9%) 9 (32.1%) 5.1
III 10 3 (30.0%) 3 (30.0%) 3.1
CLIP score 1 or 2 27 10 (37.0%) 0.172
b 15 (55.6%) 0.041
b 7.0 0.001
d
3 21 3 (14.3%) 5 (23.8%) 3,8
4 or 5 17 5 (29.4%) 6 (35.3%) 3.5
Treatment groups Regular 27 9 (33.3%) 0.414 14 (51.9%) 0.127 6.0 0.447
Split-dose 38 9 (23.7%) 12 (31.6%) 5.2
Courses 1 34 4 (11.8%) 0.005 6 (17.6%) < 0.001 3.5 < 0.001
> 1 31 14 (45.2%) 20 (64.5%) 7.9
Responder Yes 18 18 (100%) NC 18 (100%) NC 9.5 0.004
No 47 0 8 (17.0%) 4.5
Disease control Yes 26 18 (69.2%) NC 26 (100%) NC 10.6 < 0.001
No 39 0 0 3.8
apatients with ECOG score 0 versus 1 and 2 combined.
bPatients with Okuda stage I versus those with II + III; patients with CLIP score 1 or 2 versus those with score > 2.
cOverall, P = 0.004; Okuda I versus II, P = 0.013; II versus III, P = 0.193.
NC, not calculated.
dOverall, P = 0.001: CLIP 1 or 2 versus 3, P = 0.011; CLIP 3 versus >3, P = 0.432.
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were age older than 60 years (7.0 versus 5.1 months,
P = 0.05), positive anti-HCV antibody (7.6 versus
5.4 months, P = 0.033), ECOG performance status = 0
(7.0 versus 5.1 months, P = 0.011), total tumor dia-
meters less than or equal to 8 cm (7.1 versus 4.2
months, P = 0.001), absence of ascites (6.0 versus 3.6
months, P = 0.014), presence of extrahepatic metastasis
(7.1 versus 3.7 months, P = 0.014), Child-Pugh classifi-
cation A (7.0 versus 3.8 months, P = 0.012), Okuda
stage I (7.0 versus 5.1 (stage II) and 3.1 (stage III)
months, P = 0.004), CLIP score 1 or 2 (7.0 versus 3.8
(score 3) and 3.5 (score 4 or 5) months, P = 0.001),
completion of more than one course of FMP
chemotherapy (7.9 versus 3.5 months, P < 0.001),
achievement of clinical responses (9.5 versus 4.5
months, P = 0.004) and achievement of disease control
(10.6 versus 3.8 months, P < 0.001).
Cox proportion hazard model was used to evaluate the
independent factors associated with overall survival. Of
the 12 significant factors identified from univariate ana-
lysis, 11 were included for multivariate analysis. CLIP
score was not included since all 4 components of this
score had already been analyzed as individual variables.
It was found that only Child-Pugh stage B (hazard ratio
[HR], 2.216; 95% confident interval [CI], 1.257 - 3.905; P
= 0.006), presence of extrahepatic metastasis (HR, 0.574;
95% CI, 0.330 - 0.995; P = 0.048), and achievement of
disease control (HR, 0.228; 95% CI, 0.123 - 0.428; P <
0.001) were significantly associated with overall survival.
The adjusted HR of other non-significant factors (P >
0.05) were age older than 60 years (1.194; 95% CI, 0.599
- 2.379), positive anti-HCV antibody (1.131; 95% CI,
0.489 - 2.614), ECOG performance status > 0 (2.005;
95% CI, 0.995 - 3.999), total tumor diameters > 8 cm
(1.028; 95% CI, 0.430 - 2.460), absence of ascites (0.851;
95% CI, 0.344 - 2.104), Okuda stage I (1.387; 95% CI,
0.483 - 3.979), completion of more than one course
(0.499; 95%, 0.245 - 1.013) and achievement of clinical
responses (1.826, 95% CI, 0.600-5.555). In order to fol-
low the rule of 1 variable for 10 deaths, Cox propor-
tional hazard model was also performed by including
only six most significant factors obtained from univari-
ate analysis (P ≦ 0.011; Table 3). It was found that only
achievement of disease control (HR, 0.158; 95% CI,
0.051 - 0.485; P = 0.001) remained significantly asso-
ciated with overall survival.
Logistic regression analysis was used to evaluate inde-
pendent factors predicting disease control. Six signifi-
cant factors identified from univariate analysis were
included for multivariate logistic regression analysis
(CLIP score was not included). It was found that only
anti-HCV antibody (odds ratio [OR], 9.219; 95% CI,
2.233 - 38.056; P = 0.002) tumor size (OR, 0.816; 95%
CI, 0.674 - 0.987; P = 0.036), and previous anti-cancer
therapy (OR, 0.195; 95% CI, 0.051 - 0.749; P = 0.017)
were significantly associated with successful disease
control.
Adverse effect
The adverse effect found in patients receiving regular or
split-dose protocol was compared (Table 4). Because dif-
ferent numbers of treatment courses were received
among patients, all toxicity listed was assessed after the
first course of chemotherapy. In patients receiving regu-
lar therapeutic protocol, the following grade 3 to 4 toxi-
cities were observed in more than 10% of patients:
leucopenia (37.0%), neutropenia (51.9%), thrombocyto-
penia (18.5%), renal toxicity (11.1%), bleeding (11.1%),
and infection (11.1%). On the other hand, in patients
Table 4 Comparison of the maximum severity of toxicity
between the two treatment groups
NCI Common Toxicity Criteria
Grade
Toxicity Treatment
group
0 1 2 3 4 Grade 3/4
(%)
P
Leucopenia Regular 2 7 8821 0 (37.0%) 0.079
Split-dose 19 10 3606 (15.8%)
Neutropenia Regular 8 3 2771 4 (51.9%) 0.0005
Split-dose 26 3 5404 (10.5%)
Anemia Regular 3 15 8101 (3.7%) > 0.1
Split-dose 5 22 9202 (5.3%)
Thrombocytopenia Regular 6 8 8325 (18.5%) > 0.1
Split-dose 23 8 4303 (7.9%)
Nausea Regular 14 11 2000 > 0 . 1
Split-dose 19 14 5000
Vomiting Regular 23 2 2000 > 0 . 1
Split-dose 29 7 2000
Mucositis Regular 22 0 5000 > 0 . 1
Split-dose 29 6 1202 (5.3%)
Diarrhea Regular 18 8 1000 > 0 . 1
Split-dose 29 6 1202 (5.3%)
Skin rash Regular 27 0 0000 > 0 . 1
Split-dose 37 1 0000
Fatigue Regular 13 9 3202 (7.4%) > 0.1
Split-dose 19 11 7101 (2.6%)
Renal Regular 23 1 0303 (11.1%) 0.067
Split-dose 37 1 0000
Liver dysfunctiona Regular 27 0 0000 > 0 . 1
Split-dose 35 0 3000
Bleeding Regular 20 3 1303 (11.1%) > 0.1
Split-dose 35 2 0101 (2.6%)
Infection Regular 23 0 1033 (11.1%) > 0.1
Split-dose 29 2 4303 (7.9%)
aJaundice, Asterixis, and Hepatoencephalopathy were graded as grade 2, 3,
and 4, respectively according to the criteria.
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nia (15.8%) and neutropenia (10.5%) were observed in
more than 10% of patients. When the two groups were
compared, patients receiving regular treatment protocol
had a higher risk of grade 3/4 neutropenia (51.9 versus
10.5%, P = 0.0005; power = 96.2%). Furthermore,
3 patients treated with regular protocol had grade 4 (life-
threatening) infection and 2 of them died. In contrast,
3 patients treated with split-dose protocol had grade
3 infection and all of them recovered after antibiotics
treatment.
Discussion
Before sorafenib was made available, TACE was the
mainstay of treatment for eligible advanced HCC
patients. Although no large-scale randomized study has
been conducted, the palliative effect is well recognized.
The median survivals in the literature ranged from 12.7
to 34 months, with most studies reporting a consistent
median survival of 12.7 to 17 months [7-15]. It is now
evident that sorafenib is effective in treating unresect-
able HCC patients after completion of the two phase-III
s t u d i e s[ 1 6 , 1 7 ] .H o w e v e r ,i nt h eS H A R Ps t u d y ,m o s t
patients included were likely eligible for TACE. The
median survival in the treatment group was 10.7
months. It is therefore questionable as to whether sora-
fenib should replace TACE in treating TACE-eligible
patients. Additionally, in these studies, over 95% of
patients included were Child-Pugh classification A,
whereas in TACE studies, Child-Pugh classification B
patients were usually included [8-15]. Finally, in both
large-scale phase III studies, no statistical significance
was observed between treatment and control groups in
advanced HCC patients with extrahepatic metastasis
[16,17]. Therefore, the use of systemic combination che-
motherapy agents with higher response rates remains an
option when treating HCC patients with distal metasta-
s i s .O ft h em o s te f f e c t i v es i n g l eo rc o m b i n a t i o nc h e -
motherapy agents against HCC, anthracycline-based
agents, such as doxorubicin, were notorious for causing
cardiotoxicity. The cardiotoxicity might present as
alteration of electrocardiac conductivity leading to
arrhythmias, or as cardiomyopathy causing congestive
heart failure. Along with other side effects, both doxoru-
bicin and etoposide caused myelosuppression, which put
patients at risk of severe infection. Furthermore, etopo-
side, albeit rarely, could cause acute myeloid leukemia.
Among the combination agents that have been used for
Phase II clinical trials, FMP appeared to have a consis-
tent and acceptable response rate [19,20]. Although car-
diotoxicity occurred less frequently, a high risk of grade
3/4 leucopenia and neutropenia remained. In this study,
we discovered that by use of a split-dose protocol, the
risk of neutropenia could be significantly reduced. As a
result, no patient on the split-dose protocol died of neu-
tropenia-related infection.
Although statistically insignificant, patients receiving
split-dose protocol did have a slightly lower disease con-
trol rate as well as a shorter overall survival. However,
when compared with the untreated group, the overall
survival in split-dose group was still significantly pro-
longed (5.2 versus 1.5 months). Between the untreated
and split-dose group, only borderline significantly older
age was found in the untreated group (P = 0.049). This
was due to the tendency that older patients mostly
choose not to receive any treatment on the diagnosis of
far advanced HCC. Interestingly, in univariate analysis
(Table 3), it was found that older patients were more
likely to achieve disease control (P = 0.021) and had a
longer overall survival (P = 0.050). Therefore, the age
difference between the untreated and split-dose groups
did not affect our conclusion that the patients receiving
split-dose FMP treatment had a better overall survival.
Although the observation that older patients had a bet-
ter prognosis seemed unreasonable, a large-scale study
from Taiwan also indicated that HCC in younger
patients had poorer prognosis [23]. We speculated that
HCC in younger age was more invasive because cancer
cells originated from younger patients had greater
growth potential. Another seemingly possible bias is the
short survival time in the untreated group (median sur-
vival 1.5 month). In Taiwan, most of the untreated
terminal HCC patients were discharged against physi-
cian’s advice and taken home. In this study, the
untreated patients were included only when documented
overall survival time was available. According to a large-
scale study, the median overall survival time in terminal
HCC patients was 1.6 month, similar to our observation
[21].
Because of a short survival time in patients with far
advanced HCC, overall survival is a better clinical end-
point for evaluation of treatment efficacy compared to
progression free survival. In fact, of the 65 FMP-treated
patients, 24 (40%) had a survival time less than 4
months. Additionally, the median overall survival time
in the untreated patients was only 1.5 month.
A great majority of patients (65.8%) on the split-dose
protocol received only one course of therapy (Table 1).
In our hospital, the choice between the two therapeutic
protocols and the number of therapeutic courses given
were decided by the patients and attending doctors. As
a result, patients choosing the split-dose protocol usually
expressed more concern about the side effects of che-
motherapy and therefore were reluctant to accept more
than one course of therapy. It can be speculated that if
most patients on the split-dose protocol had received
more than one course of therapy, the survival could be
further improved. The present data indicated that at
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a better outcome. Clinically, physicians should encou-
rage the patients to receive more than one cycle of ther-
apy if no severe adverse reaction occurred. The present
study is, however, limited by its retrospective nature.
Although no significant association was found between
the clinicopathological factors and the treatment choice
between the two protocols, selection bias could still
occur with a small sample size. Other unrecognized fac-
tors might affect the treatment choice but were not
included in our analysis. Many patients with advanced
HCC did not choose to receive any chemotherapy nor
did they comply with a regular follow-up schedule in
the outpatient clinic. Therefore, more comprehensive
prospective, randomized study is needed before we can
conclude that the split-dose protocol is indeed beneficial
for terminal HCC patients.
It is surprising that Cox proportion hazard model
identified extrahepatic metastasis as a factor beneficial
for overall survival, albeit this finding has also been
reported in a previous study [20]. In our hospital, how-
ever, only patients with main portal vein thrombosis
and/or extrahepatic metastasis were eligible for systemic
chemotherapy. Therefore, patients without extrahepatic
metastasis in this study all had main portal vein throm-
bosis. This result could thus be interpreted as patients
who had main portal vein thrombosis had a poorer
overall survival compared with those who had distal
tumor metastasis.
Another important finding in this study was that
achieving disease control was more important than
achieving partial response in terms of improving survival,
since only achievement of disease control was included
in Cox proportional hazard model as an independent fac-
tor. Finally, it was demonstrated that patients positive for
anti-HCV were more likely to achieve disease control in
both univariate and multivariate regression analysis. On
the other hand, patients positive for HBsAg were less
likely to achieve disease control in univariate analysis.
The reason why HCV-related HCC responds better than
HBV-related HCC is unclear. This might be attributed to
different oncogenic pathways between HBV and HCV.
For example, frequent integration of HBV-DNA into
chromosome of non-cancerous liver tissue in HBV asso-
ciated HCC were reported, resulting in multi-focal clonal
population of hepatocytes [24]. As a result, HBV asso-
ciated advanced HCC might have a more complex com-
position of multi-clonal cancer cells and thus responded
less well to chemotherapy.
Conclusion
In conclusion, we discovered that by using a split-dose
protocol, the toxicity of FMP combination chemother-
apy could be drastically reduced with no significant
alteration of the overall survival. FMP chemotherapy
was more likely to achieve disease control in patients
with positive anti-HCV, smaller tumor size, and pre-
viously not having treated with anti-cancer therapy.
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